A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Public ClinicalTrials.gov record NCT06892522. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects With Multiple Myeloma
Study identification
- NCT ID
- NCT06892522
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 440 participants
Conditions and interventions
Conditions
Interventions
- Carfilzomib Drug
- Daratumumab Drug
- Dexamethasone Drug
- Etentamig Drug
- Lenalidomide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2025
- Primary completion
- Jan 31, 2036
- Completion
- Feb 29, 2036
- Last update posted
- Feb 16, 2026
2025 – 2036
United States locations
- U.S. sites
- 8
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Colorado Blood Cancer Institute /ID# 273129 | Denver | Colorado | 80218 | Recruiting |
| Moffitt Cancer Center /ID# 272628 | Tampa | Florida | 33612 | Recruiting |
| Winship Cancer Institute of Emory University /ID# 274830 | Atlanta | Georgia | 30322 | Recruiting |
| Weill Cornell Medical College /ID# 272517 | New York | New York | 10065 | Recruiting |
| University of North Carolina at Chapel Hill /ID# 274667 | Chapel Hill | North Carolina | 27514 | Recruiting |
| Atrium Health Levine Cancer Institute /ID# 276193 | Charlotte | North Carolina | 28204-2990 | Recruiting |
| Atrium Health Wake Forest Baptist Medical Center /ID# 274847 | Winston-Salem | North Carolina | 27157 | Recruiting |
| Oncology Hematology Care - Kenwood /ID# 272918 | Cincinnati | Ohio | 45236 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06892522, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 16, 2026 · Synced May 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06892522 live on ClinicalTrials.gov.